BioCentury
ARTICLE | Clinical News

Oregovomab: Interim Ph IIb QPT-ORE-002 data

February 10, 2017 8:43 PM UTC

Quest’s OncoQuest Inc. subsidiary reported interim data from the open-label, U.S. and Italian Phase IIb QPT-ORE-002 trial in 97 patients with newly diagnosed, advanced epithelial ovarian, adnexal or p...

BCIQ Company Profiles

Quest PharmaTech Inc.

BCIQ Target Profiles

CA 125